T1	HMM 335 353	antitumor activity
T2	HMM 858 958	tumor shrinkage before crossover assessed by investigator (IR) and independent central review (ICR).
T3	HMM 1102 1132	mean tumor shrinkage by IR/ICR
T4	HMM 1210 1233	Objective response rate
T5	HMM 1302 1334	Comparable disease control rates
T6	HMM 1450 1471	â‰¥3 drug-related AEs
T7	HMM 1480 1494	were rash/acne
T8	HMM 1507 1522	8.3%), diarrhea
T9	HMM 1542 1566	and stomatitis/mucositis
T10	HMM 1637 1684	with DRAEs leading to treatment discontinuation
T11	HMM 1740 1773	II, disease control rate (IR/ICR)
T12	HMM 1856 1881	showed antitumor activity
T13	HMM 2093 2119	sustained clinical benefit
